Positive final DEP irinotecan Phase 2 clinical trial results
Filed with ASX · · 8 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma Business Update
- Starpharma and Medicxi Partnership Petalion Therapeutics
- S&P DJI Announces March 2024 Quarterly Rebalance
- VivaGel BV US FDA Appeal Outcome
- Viraleze shows antiviral efficacy in COVID-19 patients
Later from Starpharma
- Annual Report to shareholders
- Starpharma Receives $5.5M R&D Tax Incentive Refund
- SPL7013 Nasal Spray Australia Update
- AGM Chair's address and CEO's presentation
- SPL receives positive FDA feedback on DEP SN38 for PROC
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma